Cristian Fernández

PharmaMar (Spain) — Spain

Medicine · Health Sciences

11h-index1.5kcitations67works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(12), Retinal Diseases and Treatments(7), Lung Cancer Treatments and Mutations(7), PARP inhibition in cancer therapy(7), Glaucoma and retinal disorders(6)

Publications67 total

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Future Oncology·2025· 3 citedOpen Access
FLACS (Femtosecond-Laser-Assisted Cataract Surgery) combined with pupiloplasty in iris-lens coloboma
American Journal of Ophthalmology Case Reports·2024Open Access
Tomographic findings in the retina of unvaccinated patients with <scp>COVID</scp> pneumonia: Prospective longitudinal study
Acta Ophthalmologica·2024
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Investigational New Drugs·2023· 8 citedOpen Access
Más herbívoros salvajes para prevenir los incendios
2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
European Journal of Cancer·2023· 11 citedOpen Access
Tomographic Findings in the Retina of Unvaccinated Patients with COVID Pneumonia: Prospective Longitudinal Study
International Journal of Environmental Research and Public Health·2023Open Access
Supplementary Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
¿Es bueno que regrese la naturaleza salvaje?
2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
ESMO Open·2022· 11 citedOpen Access
The influence of the Artisan–Verisyse position on the postoperative outcomes: A systematic review and meta-analysis
Indian Journal of Ophthalmology·2022· 3 citedOpen Access
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
European Journal of Cancer·2022· 19 citedOpen Access
Acute intraocular pressure elevation after Nd:YAG laser-puncture of a post-traumatic iris cyst
American Journal of Ophthalmology·2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Clinical Cancer Research·2022· 32 citedOpen Access
Imagen multimodal en telangiectasias maculares
Archivos de la Sociedad Española de Oftalmología·2022
MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
Journal of Thoracic Oncology·2021· 1 citedOpen Access
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Gynecologic Oncology·2021· 60 cited
page 1 of 4Next →

Frequent Co-authors

Carmen Kahatt(15), Ali Zeaiter(12), Vivek Subbiah(11), José Trigo(8), Vicente Alfaro(8), Mariano Siguero(8), Geoffrey I. Shapiro(8), Daniel D. Von Hoff(7), Ernesto Wasserman(7), Víctor Moreno(7), Ahmad Awada(7), Mitesh J. Borad(6), Benjamin Besse(6), María Ángeles Sala(6), Jennifer Arrondeau(6), Jean‐Pierre Delord(6), Rebecca Kristeleit(6), Khalil Zaman(6), José Martínez-Toldos(6), Raoul Tibes(6)